- Home
- MAZE vs KALV Comparison
MAZE vs KALV Comparison
Compare MAZE & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- KALV
- Stock Information
- Founded
- MAZE 2018
- KALV N/A
- Country
- MAZE United States
- KALV United States
- Employees
- MAZE N/A
- KALV N/A
- Industry
- MAZE
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- MAZE
- KALV Health Care
- Exchange
- MAZE NYSE
- KALV Nasdaq
- Market Cap
- MAZE 523.1M
- KALV 563.1M
- IPO Year
- MAZE 2025
- KALV N/A
- Fundamental
- Price
- MAZE $9.90
- KALV $11.16
- Analyst Decision
- MAZE Strong Buy
- KALV Strong Buy
- Analyst Count
- MAZE 3
- KALV 8
- Target Price
- MAZE $25.67
- KALV $24.83
- AVG Volume (30 Days)
- MAZE 317.2K
- KALV 548.7K
- Earning Date
- MAZE 01-01-0001
- KALV 03-12-2025
- Dividend Yield
- MAZE N/A
- KALV N/A
- EPS Growth
- MAZE N/A
- KALV N/A
- EPS
- MAZE 1.25
- KALV N/A
- Revenue
- MAZE $167,500,000.00
- KALV N/A
- Revenue This Year
- MAZE N/A
- KALV N/A
- Revenue Next Year
- MAZE N/A
- KALV N/A
- P/E Ratio
- MAZE $7.92
- KALV N/A
- Revenue Growth
- MAZE N/A
- KALV N/A
- 52 Week Low
- MAZE $9.50
- KALV $7.30
- 52 Week High
- MAZE $17.00
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- KALV 44.30
- Support Level
- MAZE N/A
- KALV $11.83
- Resistance Level
- MAZE N/A
- KALV $12.50
- Average True Range (ATR)
- MAZE 0.00
- KALV 0.59
- MACD
- MAZE 0.00
- KALV -0.20
- Stochastic Oscillator
- MAZE 0.00
- KALV 6.76
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.